AI Health Tools: The Privacy Enforcement Imperative for Investors

Listen to this article · 8 min listen

Getting FDA clearance for an AI health tool proves it’s a safe and effective medical device, but that’s only half the battle. That clearance does nothing to satisfy the completely separate, and just as tough, requirements for health data privacy. You have to think of them as two different workstreams with their own documentation. Companies that don’t get this distinction right are looking at serious enforcement risk and even getting blackballed by health plans.

If you’re a privacy officer or counsel at a health AI company, this is your world. Your device review file explains what the AI model actually does. Your privacy file has to explain what happens to all the data flowing into and out of that model. You absolutely must have both files in perfect order to stay in business and out of the regulatory crosshairs.

Device Review and Privacy Compliance

When the FDA looks at Software as a Medical Device (SaMD), it’s focused on performance: clinical, analytical, and technical. This is the path companies like HeartFlow, Tempus AI, and Butterfly Network have all successfully walked to get their technologies cleared. You can see how deep they’re in this world just by looking at HeartFlow, which has built a dense patent thicket around its CT-FFR technology, a clear sign of a team that lives and breathes device regulations. Similarly, when people talk about being ready for the FDA, Tempus AI and Butterfly Network are always part of the conversation, showing they’re committed to this side of the compliance coin.

But getting that 510(k) clearance or a De Novo classification does not get you a pass on HIPAA. The FDA’s job is to look at the medical device, full stop. Meanwhile, the Office for Civil Rights (OCR) over at HHS is the one enforcing the HIPAA Security Rule, which is all about the administrative, physical, and technical safeguards for electronic protected health information (ePHI). These aren’t just different angles on the same problem. They are completely parallel and independent requirements.

And this distinction has teeth. We’re talking about more than $167 million in fines from major health-tech enforcement cases, proving that non-compliance has a very real, material cost. While some of those fines were tied to general consumer protection, the root cause was almost always the mishandling of sensitive health data. The enforcement history from HHS OCR, in particular, gives us a very clear picture of what the HIPAA Security Rule demands from anyone building AI health tools.

HIPAA’s Mandate: Data Security

The HIPAA Security Rule says that covered entities and their business associates must have safeguards in place to protect the confidentiality, integrity, and availability of ePHI. Because AI health tools ingest and process huge volumes of incredibly sensitive patient data, this rule imposes very specific architectural and operational demands on how they’re built and managed.

Let’s take a concrete example: an AI tool that helps with diagnostics. The FDA’s review is going to focus on whether its output is accurate and how it fits safely into a doctor’s workflow. The HIPAA Security Rule, on the other hand, asks a totally different set of questions:

  • The data pipeline: How is patient data ingested, stored, and moved around?
  • Access controls: Who can actually see or change the ePHI, and how do you enforce that?
  • Encryption: Is the data encrypted both when it’s sitting on a server and when it’s moving across a network?
  • Audit trails: Is there a log that tracks every single time ePHI is accessed or changed?
  • Incident response: What’s the exact plan when (not if) a data breach happens?
  • Vendor management: How are you vetting the third parties that handle ePHI for you?

This checklist isn’t just some nice-to-have. These items are the absolute foundation for any health AI product that touches ePHI. Companies that build weak security architectures or have sloppy procedures are risking more than just enforcement actions. They’re looking at catastrophic reputational damage and a total loss of customer trust.

Enforcement: HeartFlow, Tempus AI, Butterfly Network, and Privacy

You won’t find public records of privacy enforcement against companies like HeartFlow, Tempus AI, or Butterfly Network in the same way you can pull up their FDA clearance files. But the fact that a regulator like HHS OCR brings them up when discussing what “complete” regulatory readiness looks like is telling. It means that no AI health company gets a pass on privacy scrutiny, no matter how solid its FDA status is. The government agencies working in this space, as shown in things like the HHS OCR guidance on HIPAA compliance for AI, are constantly connecting these dots, even though they’re managed by different offices.

The takeaway is that because these companies are in the health AI business, they fall under the HIPAA Security Rule, and OCR’s enforcement record shows that the bar is set high. For instance, the FDA might give you the green light for an AI that spots cardiac issues, but HHS OCR is going to be asking about the security of the imaging data, the patient identifiers attached to it, and all the systems that process and move that information. One review asks what the model does, the other asks what happens to the data that feeds it. A complete compliance file has to answer both questions thoroughly.

Not having a solid privacy compliance plan is a recipe for huge financial penalties. Just look at recent FTC enforcement actions against health tech companies: BetterHelp was fined $7.8 million by the FTC, and Cerebral was hit with $7 million in fines from the FTC and DOJ. These cases show the massive financial risk of sloppy data handling, even when a medical device clearance isn’t part of the picture. The risk in health-tech is very real and very expensive.

Building Complete Compliance

So for the privacy officers and legal counsel, your job is to make sure your privacy file is just as buttoned-up as your device review file. That means you’re doing this:

  1. Run Proactive Risk Assessments: You need to be constantly looking for threats and weak spots in how you handle ePHI, from the moment it comes in the door to the day it’s archived.
  2. Implement Strong Safeguards: Put in the administrative, physical, and technical protections that meet (and preferably exceed) the HIPAA Security Rule. We’re talking encryption, tight access controls, audit logs, and secure protocols for data transmission.
  3. Have an Incident Response Plan: Develop a real, actionable plan for security incidents and breaches, and then test it regularly to make sure it actually works.
  4. Perform Vendor Due Diligence: Vet every single third-party vendor or business associate that touches your ePHI to ensure they’re HIPAA-compliant and have their own security in order.
  5. Continuously Monitor and Improve: The threats are always changing, so your security has to change, too. That means regular audits and constant updates to your security policies and tools are non-negotiable.

You absolutely need the FDA’s sign-off on device function and safety just to get in the door. But the day-to-day operation and long-term commercial success of your AI health tool are just as dependent on sticking to tough health data privacy rules. A company can go through all the work to get FDA clearance, only to have a single major privacy failure wipe out that win with fines, a trashed reputation, and a loss of market access. The only sane approach is to run privacy compliance as a parallel, equally important regulatory track, and keep both your device file and your privacy file complete and current.

Frequently Asked Questions

Does FDA clearance for an AI health tool automatically satisfy health data privacy compliance requirements?

No, FDA clearance establishes safety and efficacy as a medical device but does not automatically satisfy health data privacy compliance. These are distinct requirements, each needing dedicated attention and documentation. Companies that conflate them face increased enforcement risk.

What is the primary distinction between an FDA device review file and a privacy compliance file for an AI health tool?

A robust device review file addresses what the AI model does, focusing on its clinical, analytical, and technical performance. A complete privacy file, conversely, addresses what happens to the data around the AI tool, including how it is handled, secured, and accessed.

What specific aspects of data handling does the HIPAA Security Rule scrutinize for AI health tools?

The HIPAA Security Rule scrutinizes how patient data is ingested, stored, and transmitted, as well as access controls, encryption methods, audit trails, incident response plans, and vendor management processes for third parties handling ePHI. These are foundational to operating any health AI product that handles ePHI.

Can companies with FDA-cleared AI health tools still face privacy enforcement actions?

Yes, no AI health company, regardless of its FDA status, is exempt from privacy scrutiny. The HHS Office for Civil Rights (OCR) enforces the HIPAA Security Rule, and its enforcement record demonstrates that companies can face significant financial penalties for inadequate health data handling, even with FDA clearance.

Editorial Team

The Editorial Team at Regulated AI Health is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.